WillItSurvive
Pharma and healthcare groups · United States

Intuitive Surgical

intuitive.com ↗

Maker of da Vinci surgical robots, the dominant system for robot assisted surgery worldwide.

Hard to displace
Assessed 20 July 2026 · Evidence as of 20 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 20 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: J&J Ottava FDA de novo decision
The call

Intuitive still owns the operating room, but slowing U.S. procedure growth, antitrust litigation over instrument bundling, and two newly cleared rivals are the things worth watching, not AI.

Intuitive Surgical manufactures da Vinci surgical robots used in over 11,100 operating rooms worldwide. The company is difficult to replace because hospitals have invested in the machines, surgeons have spent years learning them, and Intuitive makes recurring money from specialized tools (EndoWrists) that only work with da Vinci systems; competitors like Medtronic's Hugo and Johnson & Johnson's Ottava are entering the market but have not yet won significant customers from existing da Vinci hospitals. The main thing to watch is whether Ottava gains traction at hospitals that are buying their first robot rather than replacing an existing da Vinci, and whether a legal challenge to Intuitive's bundling of consumables tools succeeds in changing how the company can operate.

Why
01
AI pressure: None apparent. No AI lab or agent operates on patients; OpenAI's humanoid robotics tease spooked the stock but has no surgical product. Could AI do the core job? Unlikely.
02
Bigger players: Johnson & Johnson (Ottava) and Medtronic (Hugo). Hugo cleared for urology in Dec 2025 and Ottava filed for clearance in Jan 2026, but neither has taken meaningful U.S. placement share yet. Could a giant copy it? No, they are blocked.
03
What protects it. Switching means retraining a surgeon, not swapping a vendor; 90,000 trained surgeons and 11,100+ installed systems keep hospitals locked to da Vinci.
What would change this call
J&J Ottava FDA de novo decision and first quarterly placement counts post-clearance. Shows whether Ottava can win greenfield or replacement accounts from da Vinci.
Medtronic Hugo U.S. placement growth beyond urology into other soft-tissue procedures. Shows whether Hugo expands past its narrow cleared use case into Intuitive's territory.
Ruling in In re Da Vinci Surgical Robot Antitrust Litigation (N.D. Cal. Sherman Act tying claims). An adverse ruling could force unbundling of instruments from systems, hitting recurring revenue.
Key numbers
  • Q2 2026 revenue $2.89B, up 19% YoY (2026-06-30)
  • 11,100+ da Vinci systems installed worldwide (2025-12-31)
  • Stock down 26-29% YTD despite earnings beat (2026-07-20)
Named risks
  • Certified nationwide antitrust class action alleging EndoWrist tying could compress recurring-revenue margins. Severity: high
  • Decelerating US procedure growth tied to ACA subsidy uncertainty pressures 2026 guidance. Severity: medium
  • J&J Ottava or Medtronic Hugo gaining general soft-tissue clearance could open competitive window. Severity: medium
  • Multiple product liability suits filed March 2026 signal litigation exposure around da Vinci safety. Severity: medium
  • Stock highly sensitive to sentiment, falling 11.6% after-hours on a beat due to growth-rate optics. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Johnson & Johnson MedTech (Ottava)contestingFiled FDA de novo Jan 2026, positive pivotal bariatric results May 2026, decision pending
Medtronic (Hugo)contestingFirst FDA clearance limited to urology only, Dec 2025, no general soft-tissue clearance yet
CMR Surgical (Versius Plus)contestingReceived FDA clearance Dec 2025, US commercialization just beginning
Stryker (Mako)gaining onCited as AI-enabled orthopedic robotics peer in industry analysis, May 2026
OpenAI (humanoid robotics)contestingMay 31, 2026 announcement spooked ISRG stock despite no disclosed surgical product
Questions people ask
Is Intuitive Surgical profitable in 2026?
Yes. Q2 2026 GAAP net income was $818 million on revenue of $2.89 billion, up 19% year over year, with non-GAAP EPS of $2.80 beating the $2.51 consensus, reported July 16, 2026.
Is Intuitive Surgical losing market share to Medtronic or J&J?
Not yet by disclosed data. Medtronic's Hugo cleared FDA only for urology in December 2025, and J&J's Ottava is still awaiting a general soft-tissue de novo decision as of mid-2026, while Intuitive's installed base grew to over 11,100 da Vinci systems by December 2025.
Could AI replace Intuitive Surgical's da Vinci robots?
Unlikely near-term. Intuitive holds the largest annotated surgical dataset (14-20 million procedures) and trains AI on da Vinci's own force-feedback data, per a January 2026 analysis, positioning AI as reinforcing its moat rather than replacing the regulated hardware.
Why did Intuitive Surgical stock fall in 2026 despite beating earnings?
Shares dropped 11.6% after-hours on July 16, 2026 despite a revenue and EPS beat, because U.S. procedure growth decelerated to 12% in Q2 2026 from 14% in Q1, and full-year guidance was cut to 13.5-15.5% from 18% in 2025.
Who is Intuitive Surgical's biggest competitive threat in 2026?
Johnson & Johnson's Ottava, which submitted its FDA de novo application in January 2026 and reported positive pivotal bariatric surgery results in May 2026, is the closest general soft-tissue rival, alongside Medtronic's Hugo, cleared for urology only in December 2025.
Is Intuitive Surgical facing legal risk from antitrust claims?
Yes. A certified nationwide hospital class action (In re Da Vinci Surgical Robot Antitrust Litigation) alleging Sherman Act tying was proceeding in N.D. Cal. as of April 2026, though Intuitive won a separate SIS v. Intuitive antitrust trial in January 2025, now on appeal.
Timeline
  • 2026-07-16Q2 2026 earnings beat estimates ($2.89B revenue) but shares fall 11.6% after-hours
  • 2026-05-31OpenAI humanoid robotics announcement triggers stock panic, no surgical product disclosed
  • 2026-05-05J&J Ottava reports positive pivotal bariatric surgery study results
  • 2026-03-17Product liability suits Guyton and Patel v. Intuitive filed in N.D. Cal.
  • 2026-02-01Advanced Surgical Concepts patent suit filed against Intuitive in Massachusetts
  • 2026-01-14Preliminary FY2025 results show ~$10.06-10.1B revenue, up ~20.5% YoY
  • 2026-01-07J&J submits FDA de novo application for Ottava general soft-tissue robot
  • 2025-12-31Medtronic Hugo and CMR Versius Plus both receive FDA clearances
  • 2025-09-15FDA clears da Vinci 5 software update with intraoperative case replay
  • 2025-07-01Dave Rosa becomes CEO, succeeding 15-year CEO Gary Guthart
Revision history
20 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Vertex PharmaceuticalsTenet HealthcareNovartis
More in Pharma and healthcare groups →
Sources